Krishna Institute of Medical Sciences Ltd

After a sustained rally that has outpaced the broader market by a wide margin, Krishna Institute of Medical Sciences Ltd touched a fresh all-time high of Rs 799 on 8 Jun 2026, marking a significant milestone in its price journey.

Krishna Institute of Medical Sciences Ltd (KIMS) has witnessed a significant shift in its valuation parameters, moving from an expensive to a very expensive rating, even as its stock continues to outperform the broader market. With a price-to-earnings (P/E) ratio soaring to 127.3 and a price-to-book value (P/BV) of 14.05, investors are reassessing the stock’s price attractiveness in the context of its robust returns and sector peers.

Krishna Institute of Medical Sciences Ltd (KIMS) has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators and valuation metrics despite ongoing financial challenges. The hospital sector stock’s revised Mojo Score of 56.0 and a Market Cap Grade of small-cap underpin this reassessment, signalling cautious optimism among investors and analysts alike.

Krishna Institute of Medical Sciences Ltd (KIMS) has witnessed a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This transition is underscored by a series of mixed but predominantly positive technical indicators, signalling potential strength in the hospital sector stock despite a minor day-to-day price dip.

The 50-day moving average has crossed above the 200-day moving average for Krishna Institute of Medical Sciences Ltd, signalling a golden cross on 1 Jun 2026. Yet, the stock declined 0.63% on the same day, and monthly technical indicators remain mildly bearish. This juxtaposition of signals calls for a detailed examination of the cross’s reliability.

Krishna Institute of Medical Sciences Ltd (KIMS) has witnessed a marked shift in its valuation parameters, moving from an already expensive rating to a very expensive classification. With a price-to-earnings (P/E) ratio soaring to 126.62 and a price-to-book value (P/BV) of 13.97, investors are urged to reassess the stock’s price attractiveness amid its recent strong returns and sector dynamics.

Krishna Institute of Medical Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 May 2026, providing investors with an up-to-date view of its performance and outlook.

Krishna Institute of Medical Sciences Ltd (KIMS) has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. Despite a modest daily gain of 1.40%, the stock’s technical indicators present a nuanced picture, with bullish signals emerging on weekly charts while monthly metrics remain cautiously bearish. This article analyses the recent price momentum, key technical indicators such as MACD, RSI, moving averages, and their implications for investors navigating the hospital sector’s small-cap landscape.

Krishna Institute of Medical Sciences Ltd (KIMS) has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Despite a recent downgrade in its Mojo Grade from Strong Sell to Sell, the stock’s price action and technical indicators present a complex picture for investors navigating the hospital sector’s evolving landscape.

Krishna Institute of Medical Sciences Ltd (KIMS) has experienced a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. This change, coupled with a recent downgrade in its Mojo Grade from Strong Sell to Sell, reflects evolving market perceptions and raises questions about the stock’s price attractiveness relative to its historical and peer benchmarks.

Krishna Institute of Medical Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 April 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 17 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Krishna Institute of Medical Sciences Ltd. (KIMS) reported a concerning quarter for Q4 FY26, with consolidated net profit plummeting 58.25% year-on-year to ₹42.50 crores despite robust revenue growth of 34.85%. The hospital chain's profitability was severely impacted by escalating interest costs and declining operating margins, raising serious questions about the sustainability of its aggressive expansion strategy. The stock, currently trading at ₹761.60 with a market capitalisation of ₹30,253 crores, has declined 1.77% in recent trading as investors digest the troubling earnings trajectory.

Krishna Institute of Medical Sciences Ltd (KIMS) has witnessed a marked shift in its valuation parameters, moving from an already expensive rating to a very expensive classification. This change, coupled with a significant price appreciation of 8.65% on 12 May 2026, invites a closer examination of the stock’s price attractiveness relative to its historical averages and peer group within the hospital sector.

While the Sensex declined by 1.10% on 11 May 2026, Krishna Institute of Medical Sciences Ltd surged 7.25%, hitting an intraday high of Rs 764.25. This 5.5 percentage-point outperformance over its Hospital sector peers highlights a distinctly stock-specific rally in an otherwise weak market environment.

Krishna Institute of Medical Sciences Ltd (KIMS) has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a mildly bullish trend on weekly charts. Despite a modest day gain of 0.93% to close at ₹707.55, the stock’s technical indicators present a complex picture, blending bullish signals with cautionary notes from monthly trends and moving averages. This nuanced technical landscape warrants a detailed analysis for investors seeking clarity on KIMS’s near-term prospects.